The management of acute myeloid leukemia has shifted fundamentally as molecular profiling has revealed distinct disease subtypes with varying prognoses and therapeutic vulnerabilities. Cytogenetic analysis remains a cornerstone of acute myeloid leukemia (AML) diagnostics, providing essential information about chromosomal abnormalities that inform risk stratification and guide therapeutic decisions.1 Comprehensive genomic testing has now complemented traditional karyotyping, refining understanding of disease biology.1
Recurrent mutations in genes including NPM1, FLT3, IDH1, IDH2, and TP53 carry prognostic and therapeutic significance.1 NPM1 mutations, present in approximately one-third of cases, have emerged as particularly informative.2 In FLT3-ITD-positive AML, the prognostic impact of allelic ratio (AR) is increasingly recognized as context-dependent, with co-occurring mutational profiles, rather than AR alone, emerging as the primary determinant of outcomes.3 NPM1-mutated AML with concurrent FLT3-ITD may still be associated with favorable outcomes, particularly when favorable-risk (FR) mutations such as CEBPA or core binding factor fusions are present, though the impact of NPM1 with FLT3-ITD remains variably reported across studies.3 The presence of favorable co-occurring mutations may influence decisions to pursue consolidation chemotherapy rather than allogeneic hematopoietic cell transplant in first complete remission, alongside considerations for FLT3 inhibitor therapy and measurable residual disease monitoring.3
Identifying actionable mutations has practical implications for treatment selection, particularly in relapsed or refractory settings where conventional regimens show limited efficacy. FLT3 inhibitors, IDH inhibitors, and menin inhibitors for NPM1-mutated and KMT2A-rearranged disease have demonstrated activity in molecularly defined populations, offering alternatives when standard approaches have been exhausted.2,3
While comprehensive sequencing panels have become standard at academic centers, adoption in community practice remains variable.4 Turnaround time, cost considerations, and interpretation of co-occurring mutations present challenges. However, clinical utility in selecting therapy makes routine testing increasingly essential.
Measurable residual disease (MRD) assessment represents another application of molecular profiling. In NPM1-mutated AML, quantitative polymerase chain reaction monitoring of the mutation-specific transcript provides a patient-specific biomarker for response assessment.5,6 This highly sensitive detection method may enable identification of subclinical disease. Additionally, MRD status following consolidation therapy has demonstrated prognostic value for predicting relapse risk.6 Serial molecular testing at relapse can identify clonal evolution and early detection of resistant subclones.7 While certain mutations predict response to specific inhibitors, others may confer resistance, underscoring complexity in molecular interpretation and the importance of comprehensive profiling throughout the disease course.7
Integration of molecular profiling into routine care represents a shift toward precision oncology. Despite challenges in testing access, clinical utility of genomic data in guiding therapeutic decisions strengthens rationale for comprehensive molecular characterization across practice settings.
Take our acute myeloid leukemia quiz to see how your knowledge compares to your peers.
